About ANCA-Associated Vasculitis
ANCA-Associated Vasculitis encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), unified by neutrophil-activating autoantibodies targeting proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA), causing necrotizing inflammation of small to medium vessels. Renal involvement with rapidly progressive glomerulonephritis and pulmonary manifestations including alveolar hemorrhage are the most immediately life-threatening features. Rituximab and cyclophosphamide have equivalent efficacy for induction, while avacopan (a C5a receptor inhibitor) has received approval as a steroid-sparing agent.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to ANCA-Associated Vasculitis trials.
ANCA serotype (PR3 vs MPO) and AAV subtype (GPA, MPA, EGPA) determine trial eligibility; many trials enroll specific subtypes only — know your ANCA titer and subtype before applying
Avacopan and other complement-targeting trials require documented active disease with BVAS score confirmation; inactive or remission-phase patients are not eligible for induction trials
Renal function trajectory (eGFR trend, dialysis dependence) critically affects eligibility; dialysis-dependent patients may be excluded from some trials while specifically enrolled in others
Patient Resources
Find recruiting ANCA-Associated Vasculitis trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for ANCA-Associated Vasculitis. Updated daily.